Latest News

According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...

Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.

According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.

Patients with triple class exposed/refractory multiple myeloma treated with belantamab mafodotin plus pomalidomide-dexamethasone achieved high clinical response rates with durable remissions, determined a post-hoc analysis of the ALGONQUIN...

Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...

According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...

According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.

The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.

The US Food and Drug Administration granted approval to isatuximab with bortezomib, lenalidomide, and dexamethasone for the frontline treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplant.

The FDA approved amivantamab plus carboplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations and disease progression on or...